HSBC Holdings plc vs Vir Biotechnology Inc. Common Stock — how do they compare? HSBC Holdings plc trades at $94.89 (market cap $322.45B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.76B). The key difference: HSBC Holdings plc is far larger — about 183.2× Vir Biotechnology Inc. Common Stock's market cap, and HSBC Holdings plc pays a 3.99% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 37 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| HSBC | VIR | |
|---|---|---|
Market Cap | $322.45B | $1.76B |
Volume | 2,058,215 | 2,764,948 |
Sector | Financials | Health |
52-Week High | $107.86 | $11.78 |
52-Week Low | $65.67 | $5.12 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $229.52B | $1.32B |
Dividend Yield | 3.99% | — |
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $94.85, up 0.56% today, with mixed technical signals showing bearish momentum but neutral oscillators. The bank demonstrates strong profitability with a 34.54% net income margin and reasonable valuation at 13.42 P/E. Recent strategic moves include expanding US wealth services and re-entering India's equity broking market, while analyst sentiment remains divided with 38% buy ratings.
HSBC presents a balanced opportunity with solid fundamentals and global expansion initiatives, though technical weakness and CFO transition risks warrant caution. The stock's current valuation appears reasonable relative to earnings power, but investors should monitor execution of growth strategies amid competitive banking landscape and potential macroeconomic headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →